Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PEG 3350

Phase 3Small molecule

PEG 3350 is one of 23 small molecule programs targeting Constipation. It is currently in Phase 3.

2

Indications

9

Total Trials

2

Active Trials

22

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic ConstipationActive, not recruiting

Chronic ConstipationPhase 3

Active, not recruiting

Competition

Competitive Landscape

40 competitors in Chronic Constipation

#DrugCompanyPhaseTrials

Resotran

Golytely

Linzess

Zelnorm

AAlfasigma S.p.A.

Chronulac

SSolvay Pharmaceuticals

Lactobacillus Reuteri

TTulane University School of Medicine

Amitiza

SSucampo Pharma Americas, LLC

Elobixibat

E. Coli Nissle 1917

KKangbuk Samsung Hospital

Macrogol 4000

IIstituto Clinico Humanitas

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Not yet recruiting

Constipation

NCT06836024

Clinical

Trials by Indication[1]

Constipation3 trials

Comparison Trial of Enema vs. PEG 3350 for Constipation

Terminated·—·N/A·NCT00467350·80 enrolled

Prucalopride in Pediatric Subjects With Functional Constipation

Completed· Takeda logo

Takeda·Phase 3·NCT01330381·215 enrolled

A Trial of Actazin Versus PEG 3350 for Maintenance Therapy in Children With Constipation

Not yet recruiting·HHamilton Health Sciences Corporation·Phase 2/3·NCT06836024·60 enrolled

Chronic constipation3 trials

To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence.

Completed· Ipsen logo

Ipsen·Phase 3·NCT00255372·88 enrolled

Study of Long-term Use of Forlax® in Elderly Patients With Chronic Constipation

Completed· Ipsen logo

Ipsen·Phase 4·NCT00276354·246 enrolled

Efficacy and Safety of PEG 3350 for Treatment of Chronic Constipation

Unknown status·FFakultas Kedokteran Universitas Indonesia·Phase 3·NCT03957668·184 enrolled

Children1 trial

Polyethylene Glycol Safety in Children

Completed·—··NCT05424757·158 enrolled

TIA1 trial

Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen

Recruiting·IIndiana University·Phase 4·NCT05821309·65 enrolled

Unspecified1 trial

Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity

Completed· Takeda logo

Takeda·Phase 4·NCT01707667·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for PEG 3350. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PEG 3350 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PEG 3350. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Takeda

Related News